On KRAS Inhibitors and Why Potency Doesn’t Equal Durability

Key Takeaways

• Potency gains not guaranteeing longer progression‑free survival
• G12D inhibitors show stronger binding than first‑gen G12C drugs
• Resistance pathways remain a major obstacle for KRAS targeting
• Combination regimens are emerging as a solution to durability
• Biomarker‑guided trials needed to identify responsive patient subsets

Pulse Analysis

The KRAS oncogene has long been labeled "undruggable," yet the approval of sotorasib and adagrasib in 2022 proved that selective inhibition of the G12C mutation is feasible. These first‑generation agents generated excitement by delivering high in‑vitro potency and rapid tumor shrinkage in a subset of non‑small cell lung cancer patients. However, real‑world experience quickly revealed modest median progression‑free survival, typically under six months, raising doubts about whether biochemical potency alone can sustain durable clinical benefit. The early results set the stage for a new wave of KRAS research presented at ASCO.

At this year’s ASCO meeting, second‑generation KRAS inhibitors targeting both G12C and the more prevalent G12D mutation entered the spotlight. Compounds such as JDQ‑443 and RMC‑4630 exhibit sub‑nanomolar IC50 values and improved tumor penetration, suggesting higher potency than their predecessors. Yet early trial data show that response durability remains limited, with resistance emerging through adaptive feedback loops, secondary mutations, and pathway re‑activation. The disconnect between laboratory potency and patient outcomes highlights a critical gap: effective blockade of KRAS must be coupled with strategies that prevent or overcome resistance.

For developers and investors, the durability challenge reshapes the KRAS market landscape. Combination approaches—pairing KRAS inhibitors with immune checkpoint blockers, SHP2 inhibitors, or downstream MAPK pathway agents—are already entering phase II studies, aiming to extend response duration and broaden patient eligibility. Moreover, biomarker‑driven enrollment, including co‑mutation profiling and circulating tumor DNA monitoring, promises to identify subpopulations that may derive lasting benefit. As the field matures, success will hinge less on raw potency and more on integrated therapeutic regimens that deliver sustained disease control.